This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Small-Cap Winners & Losers

Small-cap stocks rode high atop Thursday's best-performing major index, the Nasdaq, amid a plethora of good news out of the sector.

Penford (PENX - Get Report) shares traded furiously to catapult 32.4% on impressive results for the quarter ended May 31. The Englewood, Colo., company, which makes ingredient systems for industrial and food applications, more than doubled its income from last year to $5 million, or 54 cents a share -- double the sole analyst's estimate from Thomson Financial. Shares were changing hands at $25.65.

Among the day's most impressive winners was CryoCor (CRYO), which booked gains of some 81% after the Food and Drug Administration's advisory panel recommended pre-market-approval of the San Diego company's cryoablation system, a device that treats atrial flutter (abnormal heartbeat). The FDA's ultimate decision should come in August. Shares were up $2.05 to $4.59.

The S&P SmallCap 600 index, of which Penford is a member, climbed 0.4% to 435.27. The Russell 2000 rose 0.3% as one of its components, Comverge (COMV), surged 14.7% to $32.41 on news it will buy Enerwise Global Technologies for $75.7 million in cash, stock and subordinated convertible bonds.

Comverge, an East Hanover, N.J., energy-equipment company, said it should pull in about $9 million in revenue from Enerwise during the remaining two quarters of 2007, and expects per-share earnings accretion to begin in 2008.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs